Company: AEMD
Filing Date: 2025-06-26
Form Type: 10-K
Source: 0001683168-25-004780
Chunk: 521

Company: AETHLON MEDICAL INC
Filing Date: 2025-06-26
Form: 10-K
Item: Item 1C
Chunk 521
---
closing costs and placement agent fees as further described below. The Company intends to use the net proceeds from the offering for working
capital and general corporate purposes.

As a result of the Holder
exercising the Existing Warrants, the Company issued an aggregate of 6,200,000 shares of its common stock. The shares underlying the Existing
Warrants have all been registered on Form S-1 registration statement (Registration Number 333-278188).

The Company agreed to
file a resale registration statement registering the shares underlying the Replacement Warrants (“Resale Registration Statement”)
within ninety (90) days of the date of the Agreement and to use commercially reasonable best efforts to cause the Resale Registration
Statement to be effective on or prior to the 150th calendar day after the date of the Agreement.

Subject to the terms
of the Agreement, the Company will be required to pay certain liquidated damages if the shares underlying the New Warrants are not filed
within the ninety (90) period, as more fully described in the Agreement.

The Company further agreed
that until sixty (60) days after the closing date of the warrant exercise, it will not (other than in connection with limited enumerated
exceptions) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of common stock or common
stock equivalents or file any registration statement or any amendment or supplement (other than the registration statement registering
the shares underlying the Replacement Warrants).

In connection with the
transactions contemplated in the Agreement, the Company agreed to pay its placement agent, Maxim Group, LLC (the “Agent”)
the following compensation, (i) a cash fee equal to 6.0% of the gross proceeds received by the Company in the transactions contemplated
by the Agreement, and (ii) legal fees and out-of-pocket expenses of $15,000.

May 2024 Public Offering

On May 17, 2024,
the Company closed a public offering pursuant to which it sold an aggregate of: (i) 306,250 shares
of common stock and accompanying Class A warrants to purchase up to 306,250 shares
of common stock and Class B warrants to purchase up to 306,250 shares
of common stock, at a combined public offering price of $4.64
per share and accompanying warrants; and (ii) in lieu of common stock, pre-funded warrants to purchase 706,250 shares
of common stock and accompanying Class A warrants